{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-008009","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2023-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.200697+00:00","generated_at":"2026-06-17T23:51:00.806413+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Indaptus Therapeutics Q4/FY2022: Loss per share $1.73, cash $26.4M; Phase 1 Decoy20 trial underway","bullets":["R&D expense $1.9M in Q4 (up 90% YoY); FY R&D $6.3M (up 150% YoY).","Cash and marketable securities $26.4M as of Dec 31, 2022; runway into Q2 2024.","First patient dosed in Phase 1 Decoy20 trial for solid tumors in March 2023; three sites activated.","Net cash used in operations $13.1M for FY2022 vs $11.3M in FY2021.","Robert Martell, M.D., Ph.D. elected to Board in February 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-008009","json":"https://secwatch.observer/filing/0001493152-23-008009.json","markdown":"https://secwatch.observer/filing/0001493152-23-008009.md","text":"https://secwatch.observer/filing/0001493152-23-008009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223008009/0001493152-23-008009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223008009/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:51:00.806413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d379bceddf6326f0ae2d6c24a2c19555c4faa8d","claim":"Indaptus Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On March 17, 2023, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223008009/0001493152-23-008009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}